Zoetis Rises 1.09% Despite 280th Trading Volume Rank as Pet Product Growth and FDA Approvals Fuel Earnings Outlook

Zoetis Inc. (ZTS) rose 1.09% on August 1, 2025, with a trading volume of $0.46 billion, a 35.18% decline from the prior day. The stock ranks 280th in trading activity for the session. The company is set to release Q2 earnings on August 5, with analysts forecasting revenue of $2.4 billion and earnings of $1.61 per share. Growth is expected to be driven by companion animal products, including monoclonal antibody treatments for osteoarthritis and flea control solutions like Simparica Trio, as well as dermatology drugs such as Apoquel and Cytopoint. Recent FDA approval for Simparica Trio to prevent flea tapeworm infections is anticipated to further boost sales in upcoming quarters.

Despite a decline in livestock product sales due to the 2024 divestiture of certain feed additive portfolios, Zoetis has consistently exceeded earnings estimates, delivering an average surprise of 5.21% over the past four quarters. The company’s strong track record and positive Earnings ESP of +0.42% suggest a potential earnings beat. Analysts highlight the resilience of its companion animal segment, which has offset weaknesses in other areas, positioning Zoetis for continued performance in a competitive animal health market.

A strategy of purchasing the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to the present, significantly outpacing the 29.18% benchmark return. This highlights the efficacy of liquidity-focused approaches in capturing short-term market movements, particularly in sectors where high trading volumes drive price momentum.